Browse by author
Lookup NU author(s): Dr Ali Anwar,
Professor Stephen BourkeORCiD,
Dr Peter Middleton,
Professor Christopher WardORCiD,
Dr Robert Rutherford
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
We describe our institutional efficacy experience of azithromycin 250 mg thrice weekly in adult non-cystic fibrosis bronchiectasis. Methods: Eligibility criteria for prophylactic azithromycin included 3 exacerbations requiring rescue antibiotics over the previous 6 months. The clinical records of 56 bronchiectasis patients on azithromycin were retrospectively reviewed. Exacerbation frequency, sputum microbiology, self-reported change in sputum volume, and spirometry results were recorded. Results: Mean length of treatment was 9.1 months (7.5) and 50 patients had treatment ≥3 months. Spirometry, pre- and post-azithromycin in 29 patients, who had 3 or more months of treatment, showed a mean increase in FEV1 of 83 ml (0.14) (P = 0.005) from 1.560 to 1.643 l. There was a decrease in the exacerbation frequency from 0.81/month (SD) (0.32) pre-azithromycin to 0.41/month (0.45) (P < 0.001) post-azithromycin. Clinically significant suppression of previous sputum microbial isolates was also observed. Conclusion: Azithromycin improves exacerbation frequency, spirometry, and sputum microbiology in bronchiectasis. © 2008.
Author(s): Anwar GA, Bourke SC, Afolabi G, Middleton PG, Ward C, Rutherford RM
Publication type: Article
Publication status: Published
Journal: Respiratory Medicine
ISSN (print): 0954-6111
ISSN (electronic): 1532-3064
Altmetrics provided by Altmetric